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ABSTRACT  We examined the association between ImmunoCard Mycoplasma  test and 
particle agglutination (PA) method in Mycoplasma  pneumonia diagnosis. Subjects were 105 
pneumonia patients who were positive for ImmunoCard Mycoplasma test at initial consultation 
and followed up by PA method using paired sera. The coincidence rates of positive cases of 
ImmunoCard Mycoplasma test and positive cases of PA method were examined by generation. 
The results showed that the coincidence rate was 87.5% in aged less than 19 years, 48.8% 
in aged 20-39 years, 36.4% in aged 40－59 years, 21.1% in aged 60－79 years, and 25.0% 
in aged 80 or greater, for a total of 44.8% (47 of 105 patients). The results suggested that a 
positive result for ImmunoCard Mycoplasma test may be due to acute infection in patients aged 
19 years or less; however, 50% or more of patients aged 20 years or greater were false positive, 
which may reflect the presence of past infection.
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INTRODUCTION
   Mycoplasma pneumonia is diagnosed when 
particle agglutination (PA) or complement ﬁxation 
(CF) tests show a 4-fold or greater increase in 
antibody titer by paired sera at the time of onset and 
recovery. ImmunoCard Mycoplasma test detects 
anti-Mycoplasmal antibody (IgM) in serum using 
enzyme immunoassay and has been employed 
extensively in the clinical setting for rapid test 
without paired sera1,2）. However, doubt has been 
raised due to the number of false positives for 
ImmunoCard Mycoplasma test. For this reason we 
examined the association between the ImmunoCard 
Mycoplasma  tes t  and PA method which is 
considered the established test for diagnosis.
SUBJECTS AND METHODS
Subjects 
   We examined 105 pneumonia patients who were 
positive for ImmunoCard Mycoplasma test at initial 
consultation and who were followed up by PA 
method using paired sera (interval:14.2±2.1 days) 
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at Kawasaki Hospital, Kawasaki Medical School 
during the 5 years from April 1, 2008 to March 31, 
2013.
Methods 
   The coincidence rates between positive cases of 
ImmunoCard Mycoplasma test and positive cases 
of PA method were examined by generation (～19 
years, 20－39 years, 40－59 years, 60－79 years, 
80～years). 
   ImmunoCard Mycoplasma test kit from Meridian 
Diagnostics (Cincinnati, Ohio, USA) is used in this 
study.
   A positive PA method result is deﬁned as a 4-fold 
or greater increase in PA antibody titer by paired sera.
   This study was performed with the approval of the 
Kawasaki Medical School ethical committee.
  
RESULTS (Table)
   The  results showed that coincidence rate was 
87. 5% in aged less than 19 years, 48.8% in aged 20
－39 years, 36.4% in aged 40－59 years, 21.1% in 
aged 60－79 years, and 25.0% in aged 80 or greater, 
for a total of 44.8% (47 of 105 patients).
DISCUSSION
   Published reports have suggested the existence 
of a number of false positives for ImmunoCard 
Mycoplasma test. These reports include our report 
showing that ImmunoCard Mycoplasma test positive 
pneumonia is more frequent in individuals aged 
70 years or greater than it is in younger patients, 
and particularly frequent in patients aged 80 years 
or greater3）, and Narita’s report of 9 (36%) of 25 
positive adult patients with healthy serum4）. 
   One  exp lana t ion  may  be  t ha t  pos i t i ve 
ImmunoCard Mycoplasma test continue for an 
extended period of time, as suggested by Katayose 
et al.5） in their report of a patient who was positive 
for ImmunoCard Mycoplasma test after 256 days. 
We also experienced a patient who showed positive 
for 72 weeks6）, and Narita experienced a patient 
who was positive at 527 days 4）. 
   In this study, coincidence rate was 87.5% in 
patients aged 19 years or less. Narita et al.7） also 
reported 13 patients (92.9%) showing positive 
PA method results among 14 patients aged 16 
years or less who were positive for ImmunoCard 
Mycoplasma  test. Fuse el al.8） also reported 
all 5 patients aged 15 years or less positive for 
ImmunoCard Mycoplasma test were positive of 
PA method (100.0%). Therefore, false positive for 
ImmunoCard Mycoplasma test in younger people is 
considered to be lower. 
   However, this study revealed a coincidence rate 
of 48.8% in patients 20－39 years of age, 36.4% in 
patients 40－59 years of age, 21.1% in patients 60
－79 years of age, and 25.0% in patients 80 years 
of age or greater, showing that the higher the age 
was, the lower the coincidence rate. Therefore, it is 
thought that ImmunoCard Mycoplasma test positive 
suggests acute infection in patients aged 19 years 
or less, while it frequently reﬂects past infection in 
patients aged 20 years or greater.
   A study examining the association between 
ImmunoCard Mycoplasma test and CF method9） 
Table  Coincidence rate between positive cases of ImmunoCard Mycoplasma test and positive cases 
of PA method
Age Positive cases of IC Positive cases of PA Coincidence rate (%)
　～19 16 14 87.5
20～39 43 21 48.8
40～59 11 4 36.4
60～79 19 4 21.1
80～　 16 4 25.0
Total 105 47 44.8
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showed 37  patients (30 .3%) positive by CF 
method among 122 children and adults positive for 
ImmunoCard Mycoplasma test, which is nearly the 
same as the results in this study: 47 patients (44.8%) 
with positive PA method results among 105 patients 
positive for ImmunoCard Mycoplasma test. 
   We doubted false negatives by PA method. 
According to a study10） comparing the PCR method 
using sputum with the PA method in 339 children, 
the sensitivity at 640-titer or greater for the PA 
method in single serum was 50.0%, and sensitivity 
when a 4-fold or greater increase was observed 
in pair sera was 83.3%. This indicates that, even 
in children, the PA method returns a 50% false 
negative in single serum and a 16.7% false negative 
even in pair sera by PA method. False negatives in 
elderly patients by PA method may increase due 
to the fact that antibody production is weak. It is 
desirable to compare the PCR using sputum and PA 
methods in adult patients.
   I t  has  been  a rgued  tha t  the  me thod  o f 
differentiating between bacterial pneumonia and 
atypical pneumonia by the Japanese Respiratory 
Society scoring system is more useful than the 
examination for  ImmunoCard Mycoplasma test11）.
   Hereafter, if anti-Mycoplasmal antibody (IgM 
and IgG) in serum using ELISA method is applied 
in the clinical setting, the diagnosis of Mycoplasma 
pneumonia may become ever easier.
   As described above, a positive result for 
ImmunoCard Mycoplasma test indicates acute 
infection of Mycopalsoma pneumoniae in patients 
aged 19 years or less, whereas a 50% or more rate 
of false positive can be expected in patients aged 20 
years or greater, which may reﬂect past infection.  
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